Comparative Pharmacology
Head-to-head clinical analysis: ALCAFTADINE versus EPYSQLI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAFTADINE versus EPYSQLI.
ALCAFTADINE vs EPYSQLI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Elagolix is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively inhibits GnRH binding, resulting in suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby reducing ovarian sex hormone production.
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Clinical Note
moderateAlcaftadine + Betahistine
"The therapeutic efficacy of Betahistine can be decreased when used in combination with Alcaftadine."
Clinical Note
moderateAmphetamine + Alcaftadine
"Amphetamine may decrease the sedative activities of Alcaftadine."
Clinical Note
moderateDiethylpropion + Alcaftadine
"Diethylpropion may decrease the sedative activities of Alcaftadine."
Clinical Note
moderatePhentermine + Alcaftadine
Terminal elimination half-life 12-18 hours (mean 15 h) in adults; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Primarily renal excretion (70-80% unchanged), with 10-15% fecal elimination via biliary secretion.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine
"Phentermine may decrease the sedative activities of Alcaftadine."